An Open-Label, Drug-Drug Interaction Study Designed to Evaluate the Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Subjects
Latest Information Update: 14 Feb 2023
At a glance
- Drugs Dabigatran etexilate (Primary) ; Relacorilant (Primary)
- Indications Cushing syndrome
- Focus Pharmacokinetics
- Sponsors Corcept Therapeutics
Most Recent Events
- 07 Feb 2023 Status changed from active, no longer recruiting to completed.
- 25 Aug 2022 Planned End Date changed from 1 Jun 2022 to 1 Dec 2022.
- 25 Aug 2022 Status changed from not yet recruiting to active, no longer recruiting.